The data that they have acquired with Iressa, which also targets the epidermal growth factor receptor (EGFR), is that it only works 10% of the time. 90% have no benefit. These studies were done with lung cancer patients (which it was designed for) with adenocarcinoma and only as a last resort after conventional forms of treatment have failed. It has shown very dramatic results in some patients. They are trying it with H&N patients. I have no idea of the success rates.